

Program/Inhaled Therapies for TB: Tokyo Meeting

Day 1 Session 1: Opportunities and Clinical Experience. Moderators: E Nardell and LS Schlesinger. Rapporteurs: PB Fourie, S Swaminathan		
Speaker	Suggested (Placeholder) Title—not mandatory	Time
Hiroshi Terada [NUPALS]	Welcome and Opening Remarks	10:00 AM
Andrey Maryandyshev [Northern State Medical U, Archangelsk]	A review of the Russian clinical experience with inhaled therapies for TB	10:05 AM
Larry S. Schlesinger [Ohio State U]	Key molecular switches that affect the behavior of human macrophages: potential therapeutic tar	10:35 AM
Coffee Break		
Edward Nardell [Harvard Sch. Public Health]	Capreomycin: Phase I development and potential for “therapeutic isolation” of patients	11:05 AM 11:30 AM
Soumya Swaminathan [Nat’l Instt of Res on TB, Chennai]	Clinical trial design for inhaled TB therapies in the Indian setting	12:00 PM
Bernard Fourie [U of Pretoria]	Capreomycin clinical trials	12:30 PM 1:00 PM
Lunch		
Mridula Bose [VP Chest Instt, Delhi]	Factoring human diversity in trial design	1:30 PM
Norio Doi [Res Instt. of TB, JATA, Tokyo]	Drugs of choice for inhaled therapies	2:00 PM 2:30 PM
Rapporteurs’ presentation and discussion		
Coffee Break		
Day 1, Session 2: The Host–Pathogen Dialectic in TB. Moderators: V Deretic, PB Fourie. Rapporteurs: J Keane, B Robertson		
Vojo Deretic [U of New Mexico]	Autophagy as an effective host response in TB	3:30 PM
Joseph Keane [Trinity College, Dublin]	Apoptosis as an effective host–defence strategy against TB	4:00 PM
Brian Robertson [Imperial College, London]	Imaging TB	4:30 PM
Amit Misra [CSIR Central Drug Research Instt]	Suppression of cytokine signaling and cross–regulation of SOCS and CIS	5:00 PM
Day 2; Session 3: Formulation, Evaluation, Devices. Moderators: P Colombo, H Terada. Rapporteurs: H Okamoto, L Garcia–Contreras		
Kimiko Makino [Tokyo U of Science]	Particles that can penetrate into granuloma	10:00 AM
Lucila Garcia–Contreras [U of Oklahoma]	Drug and vaccine delivery by inhalation— different challenges, different solutions	10:30 AM
Erik Frijlink [U. of Groningen]	Twincer, Cyclops, and devices for inhaled therapies for TB	11:00 AM
Coffee Break		
Hirokazu Okamoto [U. of Nagoya]	Supercritical methods for preparing inhalable particles	11:30 AM 11:45 AM
Paolo Colombo [U of Parma]	Formulations	12:15 PM
Lunch		
Keiji Hirota [Tokyo U of Science]	Venturi inhalation apparatus	1:15 PM 2:00 PM
Hiroshi Terada [NUPALS]	Formulations	2:30 PM
CF Rossi [U of Perugia]	Formulations	3:00 PM
Coffee Break		
Sally–Ann Cryan [Royal Coll. Surg, Ireland]	High–content screening	3:30 PM 4:00 PM
Rapporteurs’ presentation and discussion		
Free Communications		
Dinner		
Day 3; Session 4: Biological Payloads. Moderators: M Gonzalez–Juarrero, B. Robertson. Rapporteurs: D Hokey, P Muttli		
Sangeeta Bhaskar [National Instt. of Immunology]	Immunogenicity and protective efficacy of a whole bacteria candidate vaccine by aerosol route of immunisation	10:00 AM
Pavan Muttli [U of New Mexico]	Inhaled BCG Vaccine	10:30 AM
Jenny Ka–Wing Lam [Hong Kong Med U]	Inhaled siRNA targeting host molecules	11:00 AM
Coffee Break		
Mercedes Gonzalez–Juarrero [U of Colorado]	siRNA and miRNA against host molecules	11:30 AM 12:00 PM
David Hokey [Aeras Foundation]	Development status of inhaled TB vaccine	12:30 PM
Rapporteurs’ presentation and discussion		
Lunch		
Day 3; Session 5: Translating Inhaled Therapies for TB. Moderators: A Hickey, B Fourie, Rapporteurs: A Misra, K Makino		
UD Gupta NJIL, Agra	Preclinical testing for drug efficacy: mice, guinea pigs, monkeys	2:30 PM
Anthony Hickey [Research Triangle Instt]	Logistics: Manufacture, packaging, distribution and patient instructions for Phase I/II Clinical	3:00 PM
Ann Rawkins/Helen McShane	Preclinical and clinical efficacy of inhaled vaccines	3:30 PM
Richard Hafner	Organising clinical trials	4:00 PM
Rapporteurs’ presentation and discussion		
Closure		